178 related articles for article (PubMed ID: 19126873)
21. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
22. Dual color FISH on CBF primary acute myeloid leukemia.
Sorour A; Nafea D
Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
24. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
Hospital MA; Prebet T; Bertoli S; Thomas X; Tavernier E; Braun T; Pautas C; Perrot A; Lioure B; Rousselot P; Tamburini J; Cluzeau T; Konopacki J; Randriamalala E; Berthon C; Gourin MP; Recher C; Cahn JY; Ifrah N; Dombret H; Boissel N
Blood; 2014 Aug; 124(8):1312-9. PubMed ID: 25006122
[TBL] [Abstract][Full Text] [Related]
25. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).
Ustun C; Morgan E; Moodie EEM; Pullarkat S; Yeung C; Broesby-Olsen S; Ohgami R; Kim Y; Sperr W; Vestergaard H; Chen D; Kluin PM; Dolan M; Mrózek K; Czuchlewski D; Horny HP; George TI; Kristensen TK; Ku NK; Yi CA; Møller MB; Marcucci G; Baughn L; Schiefer AI; Hilberink JR; Pullarkat V; Shanley R; Kohlschmidt J; Coulombe J; Salhotra A; Soma L; Cho C; Linden MA; Akin C; Gotlib J; Hoermann G; Hornick J; Nakamura R; Deeg J; Bloomfield CD; Weisdorf D; Litzow MR; Valent P; Huls G; Perales MA; Borthakur G
Cancer Med; 2018 Sep; 7(9):4447-4455. PubMed ID: 30117318
[TBL] [Abstract][Full Text] [Related]
26. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Frassoni F; Milpied N; Attal M; Blaise D; Meloni G; Iori AP; Michallet M; Willemze R; Deconninck E; Harousseau JL; Polge E; Rocha V
J Clin Oncol; 2008 Jul; 26(19):3183-8. PubMed ID: 18506024
[TBL] [Abstract][Full Text] [Related]
27. Equivalent outcome of autologous stem cell transplantation and reduced intensity conditioning stem cell transplantation in acute myeloid leukemia patients with t(8;21).
Eom KS; Kim HJ; Cho BS; Lee SE; Yahng SA; Yoon JH; Shin SH; Jeon YW; Kim JH; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Acta Haematol; 2015; 133(3):266-76. PubMed ID: 25413265
[TBL] [Abstract][Full Text] [Related]
28. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
29. [A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia].
Wang B; Hua XY; Lin RR; Yang B; Wu W; He B; Zhang XW; Xing SS; Li HQ
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):796-802. PubMed ID: 31665853
[No Abstract] [Full Text] [Related]
30. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Jung HA; Maeng CH; Park S; Kim SJ; Kim K; Jang JH; Jung CW
Anticancer Res; 2014 Feb; 34(2):1037-45. PubMed ID: 24511052
[TBL] [Abstract][Full Text] [Related]
32. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
33. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
Zhu HH; Zhang XH; Qin YZ; Liu DH; Jiang H; Chen H; Jiang Q; Xu LP; Lu J; Han W; Bao L; Wang Y; Chen YH; Wang JZ; Wang FR; Lai YY; Chai JY; Wang LR; Liu YR; Liu KY; Jiang B; Huang XJ
Blood; 2013 May; 121(20):4056-62. PubMed ID: 23535063
[TBL] [Abstract][Full Text] [Related]
34. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
35. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
36. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
37. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Farag SS; Archer KJ; Mrózek K; Vardiman JW; Carroll AJ; Pettenati MJ; Moore JO; Kolitz JE; Mayer RJ; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2002 Nov; 21(5):1041-51. PubMed ID: 12370753
[TBL] [Abstract][Full Text] [Related]
38. Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
Beyar-Katz O; Lavi N; Ringelstein-Harlev S; Henig I; Yehudai-Ofir D; Haddad N; Fineman R; Ofran Y; Nov Y; Sahar D; Moustafa-Hawash N; Rowe JM; Zuckerman T
Leuk Lymphoma; 2019 Oct; 60(10):2449-2456. PubMed ID: 30943060
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
40. [Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
Numata A; Fujimaki K; Aoshima T; Onizuka M; Hagihara M; Miyazaki K; Fujita H; Sakai R; Machida S; Tanaka E; Nakajima Y; Hattori Y; Tanaka M; Yamazaki E; Shirasugi Y; Inoue Y; Watanabe S; Fujisawa S
Rinsho Ketsueki; 2012 Jul; 53(7):698-704. PubMed ID: 22975772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
